Literature DB >> 8865124

Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation.

N Takigawa1, Y Segawa, M Okahara, Y Maeda, I Takata, M Kataoka, M Fujii.   

Abstract

In an attempt to determine the prognostic significance of pretreatment factors for patients with advanced non-small cell lung cancer (NSCLC), 24 pretreatment clinical variables were analyzed for 185 patients with NSCLC who underwent chemotherapy and/or radiotherapy between 1985 and 1994. Following univariate analysis, we applied two multivariate statistical techniques. In a Cox regression mode, independently significant factors influencing patient survival included performance status (PS), disease stage, hemoglobin level, and serum calcium level. Recursive partitioning and amalgamation (RPA) resulted in three distinct prognostic subgroups based on PS, stage, weight loss, and hemoglobin level. The best survival was observed for patients with a good PS and Stage III disease who had a hemoglobin level > 11 g/dl. The worst survival was observed for patients with a poor PS and presence of weight loss irrespective of stage. All other patients had an intermediate prognosis. Median survival times were 95.1 weeks, 17.1 weeks and 39.3 weeks, respectively (P < 0.00005). The results of our analyses show that three important prognostic subgroups could readily be discerned using RPA.

Entities:  

Mesh:

Year:  1996        PMID: 8865124     DOI: 10.1016/0169-5002(96)00571-5

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  13 in total

1.  [Survival time of exclusively irradiated NSCLC patients: the viewpoint of a clinical biologist. Concerning the article by R. Wilhelm et al in Strahlenther Onkol 1988: 174:128-32 (No. 3)].

Authors:  J Watine; R Fintelmann; J C Charet
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

2.  How accurate are physicians in the prediction of patient survival in advanced lung cancer?

Authors:  Christelle Clément-Duchêne; Charlotte Carnin; Francis Guillemin; Yves Martinet
Journal:  Oncologist       Date:  2010-06-17

3.  Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Rhizlane Belbaraka; Olivier Trédan; Isabelle Ray-Coquard; Giselle Chvetzoff; Agathe Bajard; David Pérol; Nabil Ismaili; Mohammed Ismaili; Hassan Errihani; Thomas Bachelot; Paul Rebattu
Journal:  BMC Res Notes       Date:  2010-06-10

4.  Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis.

Authors:  O U Ataman; S M Bentzen; M I Saunders; S Dische
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

5.  The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.

Authors:  Yaqi Huang; Siqi Wei; Nan Jiang; Lijuan Zhang; Siyuan Wang; Xiaona Cao; Yue Zhao; Peiguo Wang
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

6.  [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].

Authors:  Ling Dai; Jian Fang; Jun Nie; Weiheng Hu; Xiaoling Chen; Jindi Han; Guangming Tian; Sen Han; Xuyi Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-11

7.  Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Authors:  Matthias Scheffler; Thomas Zander; Lucia Nogova; Carsten Kobe; Deniz Kahraman; Markus Dietlein; Irini Papachristou; Lukas Heukamp; Reinhard Büttner; Ron Boellaard; Adriaan A Lammertsma; Silvia Querings; Erich Stoelben; Walburga Engel-Riedel; Bernd Neumaier; Jürgen Wolf
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

8.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.

Authors:  H S Parra; R Cavina; F Latteri; P A Zucali; E Campagnoli; E Morenghi; G C Grimaldi; M Roncalli; A Santoro
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

9.  Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?

Authors:  Mélanie Deberne; Stanislas Ropert; Bertrand Billemont; Catherine Daniel; Jeanne Chapron; François Goldwasser
Journal:  BMC Cancer       Date:  2014-06-10       Impact factor: 4.430

Review 10.  Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).

Authors:  Ralph Zinner; Carla Visseren-Grul; David R Spigel; Coleman Obasaju
Journal:  Int J Oncol       Date:  2015-10-29       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.